Login
$CRMD
$4.82 +$0.00 (0.0%) After hours

$CRMD SEC Filings

Filed On Filing
16 Nov 2026 Form 4: Todisco Joseph, Director

Bought 80,000 shares ($391K)

12 Nov 2026 10-Q
12 Nov 2026 8-K: Results of Operations and Financial Condition

‒ Recently announced acquisition of assets of Heron Therapeutics ‒

10 Nov 2026 CURRENT REPORT
10 Nov 2026 8-K: Regulation FD Disclosure

Good afternoon, and welcome to the CorMedix conference call. Earlier today, CorMedix and Heron issued a joint press release announcing that the companies have entered into a definitive asset purchase agreement under which CorMedix will a...

09 Nov 2026 CURRENT REPORT
09 Nov 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more

Exhibit F-1: Form of U.S. Tax Compliance Certificate for Foreign Lenders that Are Not Partnerships for U.S. Federal Income Tax Purposes

02 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

CORMEDIX THERAPEUTICS PROVIDES BUSINESS UPDATE, REAFFIRMS 2026 TOTAL REVENUE GUIDANCE, AND REPORTS THIRD Quarter Cash Position

19 Oct 2026 8-K: Regulation FD Disclosure

CORMEDIX ANNOUNCES FDA ACCEPTANCE FOR PRIORITY REVIEW OF SUPPLEMENTAL NDA FOR REZZAYO® (REZAFUNGIN) FOR PROPHYLAXIS OF INVASIVE FUNGAL DISEASES

18 Sep 2026 Form 4: Dillione Janet, Director

Received 48,909 shares by exercise or conversion

01 Sep 2026 Form 4: Blum Susan, Chief Financial Officer

Gave up 8,424 shares to cover exercise price or tax ($69.9K)

01 Sep 2026 Form 4: Hurlburt Elizabeth, Chief Operating Officer

Gave up 8,076 shares to cover exercise price or tax ($67K)

01 Sep 2026 Form 4: Zelnick Kaufman Beth, Chief Legal Officer

Gave up 8,424 shares to cover exercise price or tax ($69.9K)

13 Aug 2026 10-Q
13 Aug 2026 8-K: Results of Operations and Financial Condition

‒ Q2 2026 Net Income of $26.0 million; Adjusted EBITDA of $58.7 million ‒

07 Aug 2026 8-K: Other Events

(Consolidated with Civil Action No.: 23-cv-00150 and Civil Action No.: 23-cv-00406)

02 Jul 2026 8-K: Other Events

On June 29, 2026, CorMedix Inc. (the “Company”) effected a change in its executive leadership structure, whereby the Company’s Board of Directors has appointed Elizabeth Hurlburt, currently the Chief Operating Officer, to the newly creat...

01 Jul 2026 8-K: Changes in Registrant's Certifying Accountant

CBIZ CPAs P.C. 340 Mount Kemble Ave Suite 210N Morristown, NJ 07960 P: 973.929.3500 CBIZCPAS.COM July 1, 2026 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by C...

25 Jun 2026 S-8 POS
24 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 23, 2026, CorMedix Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The Company’s stockholders voted on the following proposals at the Annual Meeting, casting their votes as described belo...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support